Current Oncology Reports

, Volume 9, Issue 2, pp 96–101 | Cite as

Cyclooxygenase-2: A novel target in human solid tumors



The enzyme cyclooxygenase-2, which is involved in the conversion of arachidonic acid-to-prostanoid synthesis, plays a key role in many inflammatory and proliferative reactions. Experimental data have shown that prostaglandins have a central action in therapeutic targeting not only in the treatment of many inflammatory diseases but also in several types of human cancers. Inhibitors of cyclooxygenase activity seem to protect against carcinoma development and show promise as chemopreventive agents and possible target therapies. Data support new treatments for patients with solid cancers tailored to the molecular characteristics of the individual tumor.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Chandrasekharan NV, Dai H, Roos KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002, 99:13926–13931.PubMedCrossRefGoogle Scholar
  2. 2.
    Warner TD, Vojnovic I, Giuliano F, et al.: Cyclooxygenase 1, 2, and 3 and production of prostaglandin 12: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissue. J Pharmacol Exp Ther 2004, 310:642–647.PubMedCrossRefGoogle Scholar
  3. 3.
    Snipes JA, Kis B, Shelness GS, et al.: Cloning and characterization of cyclooxygenase-1b (putative COX-3) in rat. J Pharmacol Exp Ther 2005, 313:668–676.PubMedCrossRefGoogle Scholar
  4. 4.
    Thomas B, Berenbaum F, Humbert L, et al.: Critical role of C/EBP delta and C/EBP beta factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1 beta in articular chondrocytes. Eur J Biochem 2000, 267:6798–6809.PubMedCrossRefGoogle Scholar
  5. 5.
    Sano H, Kawahito Y, Wilder RL, et al.: Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995, 55:3785–3789.PubMedGoogle Scholar
  6. 6.
    Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998, 90:1529–1536.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 2000, 69:145–182.PubMedCrossRefGoogle Scholar
  8. 8.
    Marnett LJ, Rowlinson SW, Goodwin DC, et al.: Arachidonic acid oxygenation by COX-1 and COX-2. mechanisms of catalysis and inhibition. J Biol Chem 1999, 274:22903–22906.PubMedCrossRefGoogle Scholar
  9. 9.
    Smith WL: Prostanoid biosynthesis and mechanisms of actions. Am J Physiol 1992, 263:F181–F191.PubMedGoogle Scholar
  10. 10.
    Narumiya S, FitzGerald GA: Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232–235.PubMedGoogle Scholar
  12. 12.
    Simmons DL, Botting RM, Hla T: Cyclooxygenase isoenzymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56:387–437.PubMedCrossRefGoogle Scholar
  13. 13.
    Bombardier C: An evidence-based evaluation of the gastro-intestinal safety of coxibs. Am J Cardiol 2002, 89S:3D–9D.CrossRefGoogle Scholar
  14. 14.
    DuBois RN, Giardiello FM, Smalley WE: Non steroidal anti-inflammatory drugs, eicosanoids and colorectal cancer. Gastroenterol Clin North Am 1996, 25:773–791.PubMedCrossRefGoogle Scholar
  15. 15.
    Norris AE, Jackson RT, McRae C. et al.: Non steroidal anti-inflammatory drug and prostate cancer progression. Int J Cancer 1998, 77:511–515.CrossRefGoogle Scholar
  16. 16.
    Harris RE, Namboodiri KK, Farrar WB, et al.: Non steroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996, 7:203–205.PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Howe LR, Subbaramaiah K, Patel J, et al.: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 HER-2)/neu-induced breast cancer. Cancer Res 2002, 62:5405–5407.PubMedGoogle Scholar
  19. 19.
    Dannenberg AJ, Altorki NK, Boyle JO, et al.: Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001, 2:544–551.PubMedCrossRefGoogle Scholar
  20. 20.
    Williams CS, Mann M, DuBois RN: The role of cyclooxygenase in inflammation, cancer, and development. Oncogene 1999, 18:7908–7916.PubMedCrossRefGoogle Scholar
  21. 21.
    Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993, 122:518–523.PubMedGoogle Scholar
  22. 22.
    Eberhart, CE, Coffey RJ, Radhika A, et al.: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 1994, 107:1183–1188.PubMedGoogle Scholar
  23. 23.
    Raspollini MR, Amunni G, Villanucci A, et al.: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 2004, 92:806–812.PubMedCrossRefGoogle Scholar
  24. 24.
    Raspollini MR, Amunni G, Villanucci A, et al.: Cyclooxygenase-2 expression in uterine leiomyosarcomas. J Chemother 16:577–581. 2004.PubMedGoogle Scholar
  25. 25.
    Tomozawa S, Tsuno NH, Sunamio E, et al.: Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis of colorectal cancer. Br J Cancer 2000, 83:324–328.PubMedCrossRefGoogle Scholar
  26. 26.
    Denkert C, Kobel M, Pest S, et al.: Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002, 160:893–903.PubMedGoogle Scholar
  27. 27.
    Ferrandina G, Legge F, Ranelletti FO, et al.: Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002, 95:801–807.PubMedCrossRefGoogle Scholar
  28. 28.
    Chen Q, Shinohara N, Abe T, et al.: Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 2004, 108:825–832.PubMedCrossRefGoogle Scholar
  29. 29.
    Qiao L, Kozoni V, Tsioulias GJ, et al.: Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995, 1258:215–223.PubMedGoogle Scholar
  30. 30.
    Sheng HM, Shao JY, Morrow JD, et al.: Modulation of apoptosis and bcl-2 expression by prostaglandins E-2 in human colon cancer cells. Cancer Res 1998, 58:362–366.PubMedGoogle Scholar
  31. 31.
    Cramer D, Harlow B, Titus-Ernstoff L, et al.: Over the counter analgesics and risk of ovarian cancer. Lancet 1998, 351:104–107.PubMedCrossRefGoogle Scholar
  32. 32.
    Akhmedkhanov AA, Toniolo P, Zeleniuch-Jacquotte A, et al.: Aspirin and risk of epithelial cancer. Gynecol Oncol 2001, 80:286.Google Scholar
  33. 33.
    Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al.: Effect of nonsteroidal anti-inflammatory (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002, 8:202–209.PubMedGoogle Scholar
  34. 34.
    Nasi ML, Castiglione M: Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled? Ann Oncol 2002, 13:1205–1211.CrossRefGoogle Scholar
  35. 35.
    Tomozawa S, Tsuno NH, Sunami E, et al.: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000, 83:324–328.PubMedCrossRefGoogle Scholar
  36. 36.
    Masunaga R, Kohno H, Dhar DK, et al.: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000, 6:4064–4068.PubMedGoogle Scholar
  37. 37.
    Raspollini MR, Amunni G, Villanucci A, et al.: Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression are associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 2005, 15:255–260.PubMedCrossRefGoogle Scholar
  38. 38.
    Ratnasinghe D, Daschner PJ, Anver MR, et al.: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance, is chemoprevention against multidrug resistance possible? Anticancer Res 2001, 21:2141–2148.PubMedGoogle Scholar
  39. 39.
    Soriano AF, Helfrich B, Chan DC, et al.: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999, 59:6178–6184.PubMedGoogle Scholar
  40. 40.
    Hida T, Kozaki K, Muramatsu H, et al.: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000, 6:2006–2011.PubMedGoogle Scholar
  41. 41.
    Joensuu H, Robert PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056.PubMedCrossRefGoogle Scholar
  42. 42.
    Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792.PubMedCrossRefGoogle Scholar
  43. 43.
    Munkarah AR, Genhai Z, Morris R, et al.: Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 2003, 88:429–433.PubMedCrossRefGoogle Scholar
  44. 44.
    Rini B, Weinberg V, Dunlap S, et al.: Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006, 106:566–575.PubMedCrossRefGoogle Scholar
  45. 45.
    Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase inhibitor, in familiar adenomatous polyposis. N Engl J Med 2000, 342:1946–1952.PubMedCrossRefGoogle Scholar
  46. 46.
    DiSaia PJ, Bloss JD: Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003, S24–S32.Google Scholar
  47. 47.
    Gasparini G, Meo S, Comella G, et al.: The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J. 2005, 11:209–216.PubMedCrossRefGoogle Scholar
  48. 48.
    Mrozek E, Kloos RT, Ringel MD, et al.: Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metabol 2006, 91:2201–2204.CrossRefGoogle Scholar
  49. 49.
    Tsujii M, Kawano S, Tsuji S, et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705–716.PubMedCrossRefGoogle Scholar
  50. 50.
    Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000, 6:135–138.PubMedGoogle Scholar
  51. 51.
    Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:705–716.CrossRefGoogle Scholar
  52. 52.
    Kakiuki Y, Tsujii S, Tsujii M: Cyclooxygenase-2 activity altered the cell-surface in colon cancer cells and enhanced liver metastasis. Cancer Res 2002, 62:1567–1572.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Department of Human Pathology and OncologyUniversity of Florence, School of MedicineFlorenceItaly

Personalised recommendations